Offer - Urjas Oil for just ₹ 1 X
Fulviglen is a prescription medicine that is available as a Injection. It is typically used for the treatment of Breast Cancer.
The correct dosage of Fulviglen depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
The most common side effects of Fulviglen are Urinary tract infection, Flu-like Symptoms. Some other side effects of Fulviglen have been listed ahead. Normally, these side effects of Fulviglen are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
Fulviglen's effect during pregnancy is Severe and Moderate while nursing. In addition, Fulviglen's effects on the liver, heart and kidney are discussed below in the Fulviglen related warnings section.
Fulviglen is not recommended if you suffer from certain medical conditions as it can have adverse effects. Thrombocytopenia and ITP are examples of such conditions. Other contraindications of Fulviglen have been discussed in the sections ahead.
Besides this, Fulviglen may also have severe interaction with some medicines. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Fulviglen is considered not safe while driving, and is not addictive.
Fulviglen is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Female) |
|
Geriatric |
|
Is the use of Fulviglen safe for pregnant women?
Fulviglen should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Fulviglen safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Fulviglen. Immediately discontinue Fulviglen if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Fulviglen on the Kidneys?
Fulviglen has very mild side effects on the kidneys.
What is the effect of Fulviglen on the Liver?
Fulviglen can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Fulviglen on the Heart?
Very few cases of side effects of Fulviglen on the heart have been reported.
Fulviglen should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Fulviglen unless your doctor advises you to do so -
Is this Fulviglen habit forming or addictive?
Forming a habit of Fulviglen has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Fulviglen. So it is best to avoid driving.
Is it safe?
Yes, Fulviglen is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
Fulviglen is unable to treat or cure mental disorders.
Interaction between Food and Fulviglen
There isn't any research available on the side effects of taking Fulviglen with food.
Interaction between Alcohol and Fulviglen
Due to lack of research, there is no information about the side effects of taking Fulviglen with alcohol.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Faslodex® (fulvestrant)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 313